FORT WASHINGTON, Pa., April 3, 2017 /PRNewswire-USNewswire/ -- The National Comprehensive Cancer Network® (NCCN®), a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria (AUC) continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) for an additional 13 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Launched in June 2016, NCCN Imaging AUC™ currently are available for 48 NCCN Guidelines®. The newest NCCN Imaging AUC™ include recommendations for:

Anal Cancer
B-Cell Lymphomas
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Colon Cancer
Hairy Cell Leukemia
Hepatobiliary Cancers
Primary Cutaneous B-Cell Lymphomas
Rectal Cancer
Soft Tissue Sarcoma
Systemic Light Chain Amyloidosis
Testicular Cancer
T-Cell Lymphomas
Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCCN Imaging AUC™ are an easy-to-use, single source for imaging recommendations pertaining to cancer screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance as outlined within the library of NCCN Guidelines. NCCN Imaging AUC™ include all imaging procedures recommended in the NCCN Guidelines, including radiographs, computed tomography (CT) scans, magnetic resonance imaging (MRI), functional nuclear medicine imaging (PET, SPECT), and ultrasound.

NCCN Imaging AUC™ are available through a web-based user interface that provides a searchable and user-customized display of approved NCCN Imaging AUC™. The complete library of NCCN Imaging AUC™ is scheduled to be available in 2017.

The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are often the most thorough and most frequently updated clinical practice guidelines available in any area of medicine. Other NCCN Guidelines derivative products include:

The NCCN Drugs & Biologics Compendium (NCCN Compendium®) contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer. The NCCN Compendium® is recognized by public and private insurers alike, including CMS and UnitedHealthcare, as an authoritative reference for oncology coverage policy.
The NEW NCCN Radiation Therapy Compendium™ includes NCCN Guidelines recommendations pertaining to indications, modalities, clinical scenario, purpose, as well as the dosing regimens used for treatment. Additional information includes the clinical notes related to the specific recommendation.

Business Affairs Homepage